| 1.95 -0.23 (-10.55%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.77 | 1-year : | 3.17 |
| Resists | First : | 2.37 | Second : | 2.72 |
| Pivot price | 2.11 |
|||
| Supports | First : | 1.82 | Second : | 1.51 |
| MAs | MA(5) : | 2.12  |
MA(20) : | 2.16 |
| MA(100) : | 2.25 |
MA(250) : | 4.22 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 54.2 |
D(3) : | 58.4 |
| RSI | RSI(14): 40.7 |
|||
| 52-week | High : | 10.88 | Low : | 1.41 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ EBS ] has closed above bottom band by 23.5%. Bollinger Bands are 33% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.13 - 2.14 | 2.14 - 2.15 |
| Low: | 1.92 - 1.94 | 1.94 - 1.95 |
| Close: | 1.93 - 1.95 | 1.95 - 1.97 |
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to for inhalational anthrax; reactive skin decontamination lotion kits; and Trobigard, a combination drug-device auto injector product candidate; and Trobigard, a combination drug-device auto injector product candidate. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, it is developing AP003, a Naloxone multidose nasal spray; AP007, a sustained release Nalmefene injection for treatment of opioid use disorder; AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; COVID-HIG for the treatment of SARS-CoV2; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, the company provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Wed, 24 Apr 2024
Emergent BioSolutions (NYSE:EBS) Shares Cross Above Two Hundred Day Moving Average of $2.25 - MarketBeat
Thu, 07 Mar 2024
Emergent BioSolutions Inc. (NYSE:EBS) Q4 2023 Earnings Call Transcript - Yahoo Finance
Thu, 07 Mar 2024
Benchmark upgrades Emergent BioSolutions to Buy (NYSE:EBS) - Seeking Alpha
Thu, 07 Mar 2024
Emergent BioSolutions Inc (EBS) Reports Mixed Fourth Quarter and Full Year 2023 Financial Results - Yahoo Finance
Fri, 01 Mar 2024
Should You Buy Emergent Biosolutions Inc (EBS) Stock After it Has Gained 27.37% in a Week? - InvestorsObserver
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 52 (M) |
| Shares Float | 52 (M) |
| Held by Insiders | 1.8 (%) |
| Held by Institutions | 78.5 (%) |
| Shares Short | 5,700 (K) |
| Shares Short P.Month | 6,200 (K) |
| EPS | -14.86 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 12.43 |
| Profit Margin | -72.5 % |
| Operating Margin | -18.4 % |
| Return on Assets (ttm) | -4.9 % |
| Return on Equity (ttm) | -74.7 % |
| Qtrly Rev. Growth | -16.3 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 20.04 |
| EBITDA (p.s.) | -1.35 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -206 (M) |
| Levered Free Cash Flow | -103 (M) |
| PE Ratio | -0.14 |
| PEG Ratio | 0 |
| Price to Book value | 0.15 |
| Price to Sales | 0.09 |
| Price to Cash Flow | -0.5 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|